Twist Bioscience's First Profit, And the 44% Drawdown That Greeted It
Management says orders will triple again — then guides AI revenue to grow ~70%. That gap, not the EBITDA milestone, is what the market is pricing.
TWST · Earnings Call · 2026-11-12
A milestone nobody is celebrating
Twist Bioscience crossed the line it has been promising for years: positive adjusted EBITDA of $2.2 million in the fiscal fourth quarter. Revenue for the quarter was $126.6 million, up 28% year-over-year and 7% sequentially — the fifteenth consecutive quarter of sequential growth — and full-year revenue reached $459.4 million, up 22% and more than $30 million above the original fiscal 2026 guidance. Gross margin finished at 53.1% for the quarter and 52.4% for the year. And yet the stock is a mess. Twist printed a high of $205.00 on October 5, 2026, and has since fallen 44.3% in nine trading days' worth of damage — the recent tape reads bluntly: up 85% over fifteen weeks, then down 25% in nine days. The report lands squarely in that collapse. That is the tension worth unpacking: the fundamentals inflected, and the multiple didn't.The $100 million confession
The arithmetic that matters is simple. AI revenue went from $21.5 million in fiscal 2025 to $59.1 million in fiscal 2026 — 175% growth. For fiscal 2027, management guides total revenue of $550–560 million (about 21% growth) including $100 million from AI drug discovery. That is roughly 69% growth on a business that just compounded at 175%. Every analyst on the call found the same seam. Subbu Nambi of Guggenheim went straight at it: the target is the "same number you've been talking about for a while," now off a much higher base — "why would growth moderate?"“Our initial guidance is for $100 million in AI drug discovery revenue... those are programs that we can forecast with high confidence today. And so we see that there is meaningful upside on top of that assumption.” — Emily Leproust, CEO and Co-Founder · 2026-11-12 Puneet Souda of Leerink pushed harder, asking whether the ~70% revenue guide against triple-digit order growth implied a timing mismatch between bookings and recognition. Emily Leproust's answer was emphatic and, read carefully, evasive:So the ceiling is capacity, not demand. That is a good problem — but it is also the exact claim the company made a quarter ago, when it committed to "triple-digit percentage growth that we see in AI-enabled drug discovery that we know we're going to be able to deliver in 2026"“triple-digit percentage growth that we see in AI-enabled drug discovery” — Emily Leproust, CEO · 2026-08-03. The pattern is now established: a bold order-growth commitment, a conservative revenue number, and "upside" bridging the two. Investors have learned to discount the first and trade the second. What has genuinely changed is the description of the customer base. A year ago this was "dozens of accounts." Adam Laponis now notes “We've added even some of the [indiscernible] Magnificent 7 and some of the larger hyperscalers to the mix.” — Adam Laponis, Chief Financial Officer · 2026-11-12 The model building cohort that begins with $10K–$100K pilots and graduates to multi-million-dollar characterization orders is, per management, returning in repeat cycles — the run-rate discovery business, they argue, is larger than the initial data binge. That was already true in May: “the orders maybe each order may be a little bit smaller... but it's more of it” — Emily Leproust, Executive, likely CEO or similar senior role · 2026-05-04. The mechanism is not new. The scale is.By triple-digit percent growth, we mean triple-digit percent growth... what we can take to the bank today guaranteed is $100 million. And we also see a lot of upside. Some of that upside if we want to realize it, we need to add the capacity. And so that's right. It's in our hands.